HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Douglas K Graham Selected Research

c-Mer Tyrosine Kinase

3/2024Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
11/2023TAM family kinases as therapeutic targets at the interface of cancer and immunity.
9/2023Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.
3/2023Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML.
1/2023Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
1/2023Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
12/2022Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.
1/2022MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
11/2021Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.
9/2021Corrigendum to "MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system" [Pharmacology & Therapeutics 213 (2020) 107577].
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Douglas K Graham Research Topics

Disease

41Neoplasms (Cancer)
03/2024 - 01/2002
18Leukemia
10/2023 - 09/2009
11Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
09/2023 - 09/2009
9Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2024 - 07/2013
7Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/2023 - 08/2014
5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
01/2023 - 05/2006
5Melanoma (Melanoma, Malignant)
10/2019 - 05/2013
4Neoplasm Metastasis (Metastasis)
11/2023 - 08/2013
4Lung Neoplasms (Lung Cancer)
01/2022 - 09/2015
3Disease Progression
11/2021 - 01/2012
3Thrombosis (Thrombus)
01/2018 - 01/2008
3Carcinogenesis
01/2016 - 05/2010
3Glioblastoma (Glioblastoma Multiforme)
01/2016 - 07/2013
2Lymphoma (Lymphomas)
01/2023 - 07/2013
2Glioma (Gliomas)
01/2023 - 01/2020
2Hematologic Neoplasms (Hematological Malignancy)
01/2022 - 11/2016
2Hemorrhage
01/2018 - 12/2013
2Colonic Neoplasms (Colon Cancer)
10/2013 - 08/2013
2Breast Neoplasms (Breast Cancer)
10/2013 - 08/2013
2Myeloid Leukemia (Leukemia, Myelocytic)
07/2013 - 01/2013
2Aplastic Anemia (Anemia, Hypoplastic)
05/2009 - 12/2004
1Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2023
1Carcinoma (Carcinomatosis)
03/2022
1Brain Neoplasms (Brain Tumor)
01/2022
1Obesity
01/2022
1Lymphatic Metastasis
11/2021
1Leukemic Infiltration
11/2018
1Triple Negative Breast Neoplasms
11/2018
1Squamous Cell Carcinoma of Head and Neck
11/2018
1Venous Thrombosis (Deep-Vein Thrombosis)
01/2018
1Polyploidy
01/2016
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
03/2015
1Blast Crisis (Blast Phase)
03/2015
1Rhabdomyosarcoma
10/2013
1Pituitary Neoplasms (Pituitary Adenoma)
10/2013
1Prostatic Neoplasms (Prostate Cancer)
10/2013
1Stomach Neoplasms (Stomach Cancer)
10/2013
1Residual Neoplasm
08/2013
1Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
07/2013
1Nevus (Nevi)
05/2013

Drug/Important Bio-Agent (IBA)

31c-Mer Tyrosine KinaseIBA
03/2024 - 05/2010
18Phosphotransferases (Kinase)IBA
03/2024 - 01/2008
11tyrosine receptor (receptor, tyrosine)IBA
03/2024 - 01/2008
11Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
09/2021 - 09/2009
9Tyrosine Kinase InhibitorsIBA
12/2018 - 05/2013
7Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
09/2023 - 01/2012
6LigandsIBA
01/2022 - 01/2012
5MRX-2843IBA
01/2023 - 03/2016
4Proteins (Proteins, Gene)FDA Link
09/2023 - 05/2006
4UNC2025IBA
01/2019 - 09/2015
3RNA (Ribonucleic Acid)IBA
10/2023 - 05/2006
3Drug CombinationsIBA
09/2023 - 01/2023
3Therapeutic UsesIBA
11/2018 - 02/2007
3Small Interfering RNA (siRNA)IBA
11/2018 - 05/2010
3CytokinesIBA
08/2013 - 01/2008
3AgarIBA
07/2013 - 05/2010
2Vincristine (Oncovin)FDA LinkGeneric
01/2023 - 05/2010
2PhosphatidylserinesIBA
01/2023 - 12/2014
2Monoclonal AntibodiesIBA
11/2018 - 11/2014
2CollagenIBA
12/2013 - 02/2007
2LuciferasesIBA
09/2013 - 01/2013
2UNC1062IBA
07/2013 - 05/2013
2Cyclosporine (Ciclosporin)FDA LinkGeneric
05/2009 - 12/2004
1Fatty Acids (Saturated Fatty Acids)IBA
10/2023
1Lipid NanoparticlesIBA
01/2023
1dipinacoline glutamateIBA
01/2023
1venetoclaxIBA
12/2022
1Biocompatible Materials (Biomaterials)IBA
03/2022
1Immune Checkpoint InhibitorsIBA
03/2022
1osimertinibIBA
01/2022
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2020
1VemurafenibIBA
01/2019
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2018
1rociletinibIBA
12/2018
1Hemostatics (Antihemorrhagics)IBA
01/2018
1Methotrexate (Mexate)FDA LinkGeneric
03/2017
1Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
03/2016
1Propidium (Propidium Iodide)IBA
01/2016
1UNC1666IBA
03/2015
1Mitochondrial Proton-Translocating ATPases (Mitochondrial ATP Synthase)IBA
03/2015
1Pyruvic Acid (Pyruvate)IBA
03/2015
1EnzymesIBA
03/2015
1oligomycin AIBA
03/2015
1Oxidoreductases (Dehydrogenase)IBA
03/2015
1Superoxides (Superoxide)IBA
03/2015
1Adenosine Triphosphate (ATP)IBA
03/2015
1UNC569IBA
11/2013
1Interleukin-12 (IL 12)IBA
08/2013
1Interleukin-6 (Interleukin 6)IBA
08/2013
1Interleukin-10 (Interleukin 10)IBA
08/2013
1Anaplastic Lymphoma KinaseIBA
07/2013
1Pyridinolcarbamate (P23)IBA
07/2013
1Hemoglobins (Hemoglobin)IBA
03/2013

Therapy/Procedure

26Therapeutics
11/2023 - 09/2009
9Drug Therapy (Chemotherapy)
09/2023 - 11/2008
3Immunotherapy
01/2023 - 10/2019
2Aftercare (After-Treatment)
01/2022 - 12/2018
2Transplantation
08/2013 - 01/2013
1Precision Medicine
01/2022
1Drug Tapering
08/2013